[Le Bureau exécutif de l'OMS và se tenir à Genève la semaine prochaine
Le programme en français est ici : http://apps.who.int/gb/f/f_eb126.html
Ci-dessous quelques documents d'orientation intéressants.CB]
EB126/6
Santé publique, innovation et propriété intellectuelle : Stratégie mondiale
et Plan daction
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_6-fr.pdf
EB126/6 Add.1
Santé publique, innovation et propriété intellectuelle : rapport du groupe
de travail dexperts sur le financement de la recherche-développement
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_6Add1-fr.pdf
EB126/7
Suivi de la réalisation des objectifs du Millénaire pour le développement
liés à la santé
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_7-fr.pdf
EB126/8
Recrutement international des personnels de santé :projet de code de
pratique mondial
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_8-fr.pdf
EB126/12
Lutte contre les maladies non transmissibles : mise en oeuvre de la
Stratégie mondiale
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_12-fr.pdf
EB126/13
Stratégies visant à réduire lusage nocif de lalcool : projet de stratégie
mondiale
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_13-fr.pdf
EB126/20
Approche stratégique de la gestion internationale des produits chimiques
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_20-fr.pdf
EB126/21
Éléments dorientation pour lexamen par lOMS des substances psychoactives
aux fins dun
contrôle international : projet de révision
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_21-fr.pdf
-----Message d'origine-----
la part de E-drug@healthnet.org
Envoyé : mercredi 13 janvier 2010 10:01
andDevelopment Financing
E-DRUG: Report of the WHO Expert Working Group on Research and
Development Financing
-----------------------------------------------------------------
[The WHO is holding its Executive Board in Geneva in a week's time. For
the agenda and papers see: http://apps.who.int/gb/e/e_eb126.html
There is a paper on Strategic Approach to International Chemicals
Management (EB126/20;
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_20-en.pdf). Medicines
are also touched upon in the programme on Public health, innovation and
intellectual property will be discussed. The WHO website has an
executive summary of the Report of the Expert Working Group on Research
and Development Financing. Cross posted from : EQUIDAD@listserv.paho.org
and AFRONETS with thanks. WB]
Available online PDF [19p.] at:
http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_6Add1-en.pdf
*Public health, innovation and intellectual property
*WHO Report of the Expert Working Group on Research and Development
Financing*
*December 23rd, 2009
Extract:
"....There is persistent and growing concern that the benefits of the
advances in health technology are not reaching the poor. The emphasis of
the developed world is naturally on the solution of the problems that
affect it predominantly. This is in spite of the evidence of the heavy
burden of disease on the poor, which in addition to being one of the
more egregious manifestations of inequity, could undoubtedly affect
overall global stability.
There is convincing evidence of the poor bearing a double burden of
disease, but there is still no indication of adequate research and
development to address the Type II and III diseases.1 This growing focus
on the diseases of the poor has led to examination of the relationship
between intellectual property rights,2 innovation and public health, and
the gap in the innovation cycle with the concern that the commercial
incentives provided by intellectual property rights have not resulted in
sufficient improvements in public health in developing countries or to
access to the benefits of innovations that take place in the developed
world..."
1 Type 1 diseases are incident in both rich and poor countries with
large numbers of vulnerable populations in each.
Type II diseases are incident in both rich and poor countries but with a
substantial proportion of the cases in poor countries.
Type III diseases are those that are overwhelmingly or exclusively
incident in developing countries.